Utang jangka cendhak marang modal Affimed N.V. (AFMD)

Affimed (AFMD) is developing cellular immunity regulators while optimizing supply chains to protect profits and reduce costs. Developments in the fight against lymphomas remain independent of market volatility, with the key metric standing at 0.00. The business relies on a stable workforce within the R&D sector. This chart provides a visual snapshot of the price action for specific debt and the company's short positions.

Due to the non-cyclical nature of immuno-oncology drug development, Affimed possesses high macro-resilience, while the current value of 0.00 reflects the proportion of short-term liabilities to own resources, allowing for an assessment of liquidity risk and the probability of capital loss during a trend reversal through an analysis of changes in short-term debt levels relative to equity.